EP1700947A2 - Étoffe chargée de principes actifs et méthode correspondante pour la recharge en principes actifs - Google Patents

Étoffe chargée de principes actifs et méthode correspondante pour la recharge en principes actifs Download PDF

Info

Publication number
EP1700947A2
EP1700947A2 EP06004931A EP06004931A EP1700947A2 EP 1700947 A2 EP1700947 A2 EP 1700947A2 EP 06004931 A EP06004931 A EP 06004931A EP 06004931 A EP06004931 A EP 06004931A EP 1700947 A2 EP1700947 A2 EP 1700947A2
Authority
EP
European Patent Office
Prior art keywords
fabric
active principles
previous
recharging method
relevant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP06004931A
Other languages
German (de)
English (en)
Other versions
EP1700947A3 (fr
EP1700947B1 (fr
Inventor
Morena Restani
Lucio Lenzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE602006008679T priority Critical patent/DE602006008679D1/de
Publication of EP1700947A2 publication Critical patent/EP1700947A2/fr
Publication of EP1700947A3 publication Critical patent/EP1700947A3/fr
Application granted granted Critical
Publication of EP1700947B1 publication Critical patent/EP1700947B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • D—TEXTILES; PAPER
    • D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
    • D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
    • D06M15/00—Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment
    • D06M15/01—Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment with natural macromolecular compounds or derivatives thereof
    • D06M15/15—Proteins or derivatives thereof
    • D—TEXTILES; PAPER
    • D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
    • D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
    • D06M23/00—Treatment of fibres, threads, yarns, fabrics or fibrous goods made from such materials, characterised by the process
    • D06M23/12—Processes in which the treating agent is incorporated in microcapsules
    • D—TEXTILES; PAPER
    • D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
    • D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
    • D06M2101/00—Chemical constitution of the fibres, threads, yarns, fabrics or fibrous goods made from such materials, to be treated
    • D06M2101/16—Synthetic fibres, other than mineral fibres
    • D06M2101/30—Synthetic polymers consisting of macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • D06M2101/38—Polyurethanes

Definitions

  • the present invention refers to a fabric with active principles and to a recharging method of said principles having the main aim to prevent and/or to give the first cures to the diabetic foot.
  • the problems to the feet caused to ulcers, accidental injuries, micro-traumas, wounds also light, callosity and infections.
  • the persons with these pathologies have a reduced flux of blond in the inferior arts, in particular from the knee to the foot, owing to a stricture of the arteries.
  • the diabetes gives a progressive destruction of the nerves that arrive to the foot and to a skin degeneration, that becomes dry and inflexible, so easy to be subjected to wounds.
  • the concomitance of these events determines infections often careless and minimal realized to the diabetic patient, this due also to a minor sensibility of the nervous terminations of the foot.
  • the degenerative forms created to a light wound are, owing to the complications given to the metabolic, circulatory and neurological alterations, not to disregard as they easily evolve in serious pathologies, unfortunately favourite to long times for healing the wounds in the diabetic patient, with consequent increasing of risk of bacterial, viral and mycotic infections.
  • the complications of a normal disregarded ulceration are one of the more frequent causes of admission to hospital for this pathology.
  • the non-prevention and non-care of that known as diabetic foot determines the claudication and, in the grave cases, the amputation of the art.
  • a consistent percentage of diabetic persons are subjected to ulcerations to the feet that prolong in the time can grow worse.
  • To have an idea of the problem are cited the data of the Health World Organization where are counted in one hundred and twenty million the diabetic persons in year 1996 and it is estimated in three hundred million the number of diabetic persons in year 2025, where on an average the 15% will have ulcerations to the feet with complications.
  • Always from the cited sources are known data that counted that for one hundred diabetic patients with amputations eighty-four have had as cause of the amputation an ulceration to a foot grows worse in time.
  • the invention creates a fabric, for specific application in this pathology, impregnated with substances with synergetic action and gradual release, and a recharging method of said active substances when these have lost their efficacy in time.
  • the recharging of the active principles to the fabric permits a reusing of the specific fabric and it permits to have a set of clothes with controlled release of the active substances.
  • the invention consists of a fabric 1 in lycra fibres and micro-fibres (known with the trade "meryl"), in variable percentages for application of this kind, that in actuation has the form of stocking 2, pantyhose 3, sock 4, winding bandage with closed border 5, bandage or plaster 6.
  • This type of fabric has the characteristic to have fibres with minor or equal subtlety to ten micron. So the fibres of this fabric are of inferior diameter to that of the silk, that have a subtlety of the fibres of twelve micron, of the cotton with subtlety of the fibres of thirteen and half micron, of the cashmere with fibres diameter dimension of fifteen micron and of the wool with fibres diameter dimension of seventeen micron.
  • the application of this characteristic of the invention is of big importance for the diabetic foot such as more the thread is thin minor are the damages to abrasion of the fabric onto the skin. So an extremely smooth fabric is obtained that no creates micro-abrasions onto the inelastic skin and dry of the diabetic patient.
  • the fabric 1 is provided in the woof of thin silver yarns 7 with function anti-bacteric and bacteriostatic.
  • pantyhose 3, sock 4 has a sewing with flat folding 8 in the anterior part of the stocking, imperceptible to the touch.
  • the fabric 1 moreover, ha elastic property (elasticity of 99-100%) so to not obstruct the venous flux, to not worsening the occlusive peripheral arterypatia and to favourite the local microcirculation.
  • it has capacity of umidity absorption, low rate of water retention and, differently to the natural fibres, quick time of drying.
  • This active substance have had use, previous to the invention, like a cosmetic humectant and emollient ingredient and like a substance with crioprotective property.
  • Said active principle of new and original application in the treatment of the diabetic foot, has important property that opposed the dryness of the skin typical of the diabetic patient. It gives, infact, the coesion between the spinous and germinativum stratum favouring the madding and the folding of the interkeratociti liquids, so as estimated through the compression studies of the isotherms and of the multilayer of the Langmuir balance.
  • said substance stimulates the growth of the human skin fibroblast in the tests in vitro without the growth of the keratinociti, so acting onto the micro-ulcerations of the skin to their first turning up and onto all the cute surface, from the knee to the foot.
  • the active principle given to the cited substance increases the formation of elastin and of collagen type I and type IV with increasing of the cute hydration of at least the 45% in the twelve subsequent hours in comparison with a sample of skin not treated or treated with cream with the only placebo effect.
  • This substance is inserted in the wet fabric in a quantity of at least 1 mg/ml.
  • an exapeptide 10 from the alpha chain (known with trade "serilesine”).
  • This peptide increases the adhesion of the cells, favours the cellular proliferation and betters the microcirculation such as it favours the angiogenesis.
  • This active substance is added to the wet fabric 1 in quantity at least of 0,05 mg/ml. Also this last substance is never previous used for the use in pathology such that of the diabetic foot. Both these substances are previous used in the cosmetic field. So they do not present toxicity problems and they are not to be considered drugs to be prescribed with prescription.
  • the fabric 1 is then washed in water at 50°C. Ending this working the water is discharged and the fabric is wet with clean water to which is added a mordanting assistant 12, the nylofixam PM (known with trade “clariant") that has the function to bound the substances contained in the microcapsules 11 to the aminic group of the fabric 1, by means of the polarization that favours the union between the fabric 1 and the substances 9 and 10 into the microcapsules.
  • the fixer 12 is then added in proportion of 4% of the weight of the fabric 1 to treat. Then are introduced in the bath the microcapsules 11 in the dose previous described and in total quantity of the 6% of the weight of the fabric. After ten minutes is added a cationic product 13, i.e.
  • the simple application of a cream with active principles does not reach the useful results for the diabetic foot pathology such as the results obtained with the invention such as the friction of the foot with the conventional pantyhose creates, during the walk, frictions that take off the cream instead of makes it to absorb to the skin of the foot and neither the occlusive bandages with cream and gauzes are not to be used if no with the patient in bed.
  • the invention is so to be used in the daily without constraints and/or changing to the style of life of the patient.
  • the invention in the application in the form of application also winding bandage 5, cicatrizant bandage or plaster 6 have application also remedy for the bedsores and/or light wounds..
  • FIG. 1 is view of an example of production like a stocking.
  • Figure 2 is view of an application like a stock.
  • Figure 3 is view of the version like a pantyhose.
  • Figure 4 is view of the version of winding bandage with closed profile.
  • Figure 5 is view of the version of bandage or plaster.
  • sheet 2 are illustrated some sequences of the recharging phase of the active principles of the invention.
  • figure 6 is view of the immersion phase.
  • Figure 7 is view of the invention soaks in water with the active principles.

Landscapes

  • Engineering & Computer Science (AREA)
  • Textile Engineering (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP06004931A 2005-03-11 2006-03-10 Étoffe chargée de principes actifs et méthode correspondante pour la recharge en principes actifs Active EP1700947B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE602006008679T DE602006008679D1 (de) 2005-03-11 2006-03-10 Mit Wirkstoffen beladenes Gewebe, sowie entsprechendes Verfahren zum Wiederaufladen der Wirkstoffe

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000140A ITBO20050140A1 (it) 2005-03-11 2005-03-11 Tessuto con principi attivi e metodo collegato di ricarica dei principi attivi

Publications (3)

Publication Number Publication Date
EP1700947A2 true EP1700947A2 (fr) 2006-09-13
EP1700947A3 EP1700947A3 (fr) 2007-07-18
EP1700947B1 EP1700947B1 (fr) 2009-08-26

Family

ID=36581655

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06004931A Active EP1700947B1 (fr) 2005-03-11 2006-03-10 Étoffe chargée de principes actifs et méthode correspondante pour la recharge en principes actifs

Country Status (5)

Country Link
EP (1) EP1700947B1 (fr)
AT (1) ATE440994T1 (fr)
DE (1) DE602006008679D1 (fr)
ES (1) ES2332374T3 (fr)
IT (1) ITBO20050140A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2336995A1 (es) * 2008-10-13 2010-04-19 Lipotec, S.A. Composicion cosmetica o dermofarmaceutica para el cuidado de la piel, cuero cabelludo y uñas.
US9566206B2 (en) 2011-03-23 2017-02-14 SIGVARIS Inc. Graduated compression garments

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2368532A1 (fr) 2010-03-25 2011-09-28 Ganzoni & Cie AG Textiles de compression contenant des fibres revêtues de chitosan
ES2814552T3 (es) * 2014-10-31 2021-03-29 Lipotec S A U Composición cosmética y/o farmacéutica que contiene un producto extracelular bacteriano de la Pseudoalteromonas antarctica y su uso

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050027219A1 (en) * 2003-07-02 2005-02-03 Claudia Schultze Sleeve-like knitted structure for use as a castliner

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050027219A1 (en) * 2003-07-02 2005-02-03 Claudia Schultze Sleeve-like knitted structure for use as a castliner

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ELDOR, R ET AL.: "New and experimental approaches to treatment of diabetic foot ulcers: a comprehensive review of emerging treatment strategies." DIABETIC MEDICINE, JOHN WILEY & SONS, LTD, GB, vol. 21, no. 11, November 2004 (2004-11), pages 1161-1173, XP002436287 *
LIPOTEC S.A.: "Serilesine - An adhesion sequence from Laminin - revision 3" [Online] May 2004 (2004-05), , XP002436143 Retrieved from the Internet: URL:http://www.centerchem.com/PDFs/Serilesine.pdf> * the whole document * *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2336995A1 (es) * 2008-10-13 2010-04-19 Lipotec, S.A. Composicion cosmetica o dermofarmaceutica para el cuidado de la piel, cuero cabelludo y uñas.
WO2010043346A1 (fr) 2008-10-13 2010-04-22 Lipotec, S.A. Composition cosmétique ou dermato-pharmaceutique contenant un extrait de ferment de pseudoalteromonas
EP3375434A1 (fr) * 2008-10-13 2018-09-19 Lipotec, S.A. Composition cosmétique ou dermopharmaceutique contenant un extrait de ferment de pseudoalteromonas
US9566206B2 (en) 2011-03-23 2017-02-14 SIGVARIS Inc. Graduated compression garments

Also Published As

Publication number Publication date
EP1700947A3 (fr) 2007-07-18
EP1700947B1 (fr) 2009-08-26
DE602006008679D1 (de) 2009-10-08
ES2332374T3 (es) 2010-02-03
ITBO20050140A1 (it) 2006-09-12
ATE440994T1 (de) 2009-09-15

Similar Documents

Publication Publication Date Title
CA2793146C (fr) Textile de compression comprenant des fibres revetues de chitosane
WO2007048522A1 (fr) Compositions pharmaceutiques servant a guerir des blessures et se presentant sous la forme d'une creme a base d'acides amines et de hyaluronate de sodium
WO2013106410A2 (fr) Chaussette améliorée pour le traitement de plaies au pied et à la jambe, procédés d'utilisation et de fabrication
US9387125B1 (en) Sock for treatment of foot and leg wounds, methods of use and manufacture
EP1700947B1 (fr) Étoffe chargée de principes actifs et méthode correspondante pour la recharge en principes actifs
CN202932044U (zh) 抗菌防臭袜
Vachhrajani et al. Science of wound healing and dressing materials
US20090280151A1 (en) Fabric with active principles and relevant recharging method of the active principles
US7166307B1 (en) Herb medicine composition to be spread on sanitary napkin for female
CA2627223A1 (fr) Compositions pharmaceutiques servant a guerir des blessures et se presentant sous la forme d'une poudre sterile a base d'acides amines et de hyaluronate de sodium
CN101003943A (zh) 钠米抗菌棉纺织材料及其系列卫生日用品
JPH1037070A (ja) 緑茶成分カテキン含有抗菌繊維
CN106418743A (zh) 一种植物抗菌防臭袜及其制备方法
Oliveira et al. The use of textiles in the wound healing: a review
KR101821965B1 (ko) 이중파일편성구조를 구비하는 기능성 스타킹 양말
CN1874748B (zh) 用硫处理的纺织品和鞋袜类产品
Shirvan et al. Allergies caused by textiles and their control
CN103147271A (zh) 一种纳米抗抑菌棉纺织材料及其制品
FR2857876A1 (fr) Procede pour obtenir un produit manufacture en soie indique dans le traitement de certaines affections cutanees du corps humain
CN111304913A (zh) 女士内裤抗菌去味贴及其制备方法
KR200367929Y1 (ko) 나노 실버 양말
EP2667904B1 (fr) Tubes et bas de contention pourvus d'agents bioactifs pour le traitement de l'insuffisance veineuse et des varices
Marinova THE EFFECT OF TOPICAL APPLICATION WITH OZOILE® AS A NOVEL METHOD IN THE COMPLEX TREATMENT OF SOFT TISSUE INFECTIONS AND CHRONIC WOUNDS.
KR200303738Y1 (ko) 보습양말
CN101108209A (zh) 一种治疗脚气病的中药

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

17P Request for examination filed

Effective date: 20080116

17Q First examination report despatched

Effective date: 20080226

AKX Designation fees paid

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602006008679

Country of ref document: DE

Date of ref document: 20091008

Kind code of ref document: P

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BUGNION S.A.

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20090826

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090826

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091226

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090826

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090826

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2332374

Country of ref document: ES

Kind code of ref document: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090826

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090826

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090826

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090826

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091126

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090826

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090826

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090826

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090826

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090826

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090826

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090826

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20100527

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100331

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091127

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100310

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100310

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100227

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090826

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20170222

Year of fee payment: 12

Ref country code: CH

Payment date: 20170227

Year of fee payment: 12

Ref country code: FR

Payment date: 20170221

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20170224

Year of fee payment: 12

Ref country code: AT

Payment date: 20170222

Year of fee payment: 12

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: ING. MARCO ZARDI C/O M. ZARDI AND CO. S.A., CH

Ref country code: CH

Ref legal event code: PUE

Owner name: HARMONIUM INVESTMENTS LIMITED, GB

Free format text: FORMER OWNER: LVM TECHNOLOGIES S.R.L., IT

Ref country code: CH

Ref legal event code: PUE

Owner name: LVM TECHNOLOGIES S.R.L., IT

Free format text: FORMER OWNER: RESTANI, MORENA, IT

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602006008679

Country of ref document: DE

Representative=s name: MOSER GOETZE & PARTNER PATENTANWAELTE MBB, DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 602006008679

Country of ref document: DE

Owner name: HARMONIUM INVESTMENTS LTD., GB

Free format text: FORMER OWNERS: RESTANI, MORENA, CALDERATA DI RENO, IT; LENZI, LUCIO, VERGATO, IT

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20170921 AND 20170927

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20170928 AND 20171004

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: LVM TECHNOLOGIES S.R.L.

Effective date: 20171113

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: HARMONIUM INVESTMENTS LIMITED

Effective date: 20171205

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

Owner name: HARMONIUM INVESTMENTS LIMITED, GB

Effective date: 20171213

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602006008679

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 440994

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180310

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20180310

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181002

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180310

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180331

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180331

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180310

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180331

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20190904

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180311

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230228

Year of fee payment: 18